Genetics of neuroendocrine and carcinoid tumours

P D Leotlela, A Jauch\(^1\), H Holtgreve-Grez\(^1\) and R V Thakker

Molecular Endocrinology Group, Nuffield Department of Medicine, University of Oxford, Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
\(^1\)Institute of Human Genetics, University of Heidelberg, Germany

(Requests for offprints should be addressed to R V Thakker; Email: rajesh.thakker@ndm.ox.ac.uk)

Abstract

Neuroendocrine tumours (NETs) originate in tissues that contain cells derived from the embryonic neural crest, neuroectoderm and endoderm. Thus, NETs occur at many sites in the body, although the majority occur within the gastro-entero-pancreatic axis and can be subdivided into those of foregut, midgut and hindgut origin. Amongst these, only those of midgut origin are generally argentaffin positive and secrete serotonin, and hence only these should be referred to as carcinoid tumours. NETs may occur as part of complex familial endocrine cancer syndromes, such as multiple endocrine neoplasia type 1 (MEN1), although the majority occur as non-familial (i.e. sporadic) isolated tumours. Molecular genetic studies have revealed that the development of NETs may involve different genes, each of which may be associated with several different abnormalities that include point mutations, gene deletions, DNA methylation, chromosomal losses and chromosomal gains. Indeed, the foregut, midgut and hindgut NETs develop via different molecular pathways. For example, foregut NETs have frequent deletions and mutations of the \(\text{MEN1}\) gene, whereas midgut NETs have losses of chromosome 18, 11q and 16q and hindgut NETs express transforming growth factor-\(\alpha\) and the epidermal growth factor receptor. Furthermore, in lung NETs, a loss of chromosome 3p is the most frequent change and p53 mutations and chromosomal loss of 5q21 are associated with more aggressive tumours and poor survival. In addition, methylation frequencies of \(\text{retinoic acid receptor-}\beta\), \(\text{E-cadherin}\) and \(\text{RAS-associated domain family}\) genes increase with the severity of lung NETs. Thus the development and progression of NETs is associated with specific genetic abnormalities that indicate the likely involvement of different molecular pathways.

Endocrine-Related Cancer (2003) 10 437–450

Introduction

Neuroendocrine tumours (NETs) occur in tissues that contain cells derived from the embryonic neural crest, neuroectoderm and endoderm (Le Douarin 1988, Vinik 2001, Oberg 2002). Thus, NETs may occur at many sites in the body, although the majority occur within the gastro-entero-pancreatic axis (Table 1). Amongst these, more than 50% are carcinoid tumours, which are traditionally considered to be serotonin (5-hydroxytryptamine) secreting and argentaffin positive, and are sub-classified into foregut, midgut and hindgut tumours (Vinik 2001, Oberg 2002). The foregut tumours include carcinoids of the bronchus, lung, thymus, stomach, first portion of the duodenum and pancreas; the midgut tumours derive from the second portion of the duodenum, the jejunum, ileum, appendix and ascending colon; and the hindgut tumours derive from the transverse colon, the descending colon and rectum. However, it is important to note that the foregut and hindgut tumours are argentaffin negative and have a low content (or none) of serotonin. In view of this, the term carcinoid tumour is now reserved for only those midgut tumours that are serotonin secreting and the term NETs, together with the tissue of origin, is used for the other tumours (Oberg 1998). Thus, in this definition, the midgut carcinoid tumours represent a subset of NETs. NETs and carcinoid tumours usually occur as non-familial (i.e. sporadic) tumours. However, they may sometimes occur as part of familial syndromes such as multiple endocrine neoplasia type 1 (MEN1) (Oberg 1998) and neurofibromatosis type 1 (NF1) (Griffiths \textit{et al.} 1987), although the occurrence of familial isolated midgut carcinoids is rare and has been reported only five times (Eschbach & Rivaldo 1962, Anderson 1966, Kinova \textit{et al.} 2001, Oliveira \textit{et al.} 2001, Pal \textit{et al.} 2001). The familial occurrence of NETs is consistent with a genetic aetiology for NETs. This review will focus on the molecular genetic basis of NETs and carcinoid tumours, together with
a brief outline of the models for tumour development. However, it is important to note that NETs represent a heterogenous group of tumours, and that comparisons between different studies (Debelenko et al. 1997a, Dong et al. 1997, Onuki et al. 1999, Zhao et al. 2000, Ullmann et al. 2002), which have generally not used a World Health Organisation (Brambilla et al. 2001, Younossian et al. 2002) classification are therefore difficult.

Models of tumour development

The development of tumours may be associated with mutations or inappropriate expression of specific normal cellular genes, which are referred to as oncogenes (Thakker & Ponder 1988, Thakker 1993, 1994, Brown & Solomon 1997). Two types of oncogenes, referred to as dominant and recessive oncogenes, have been described. An activation of dominant oncogenes leads to transformation of the cells containing them, and examples of this are the chromosomal translocations associated with the occurrence of Burkitt’s lymphoma and the activating mutations of the RET proto-oncogene in MEN type 2. In these conditions, the mutations, which lead to activation of the oncogene, are dominant at the cellular level, and therefore only one copy of the mutated gene is required for the phenotypic effect. However, in some inherited neoplasms, which may also arise sporadically, such as retinoblastoma (RB) and MEN1, tumour development is associated with two recessive mutations, which inactivate oncogenes, and these are referred to as recessive oncogenes. In the inherited tumours, the first of the two recessive mutations is inherited via the germ cell line and is present in all the cells. This recessive mutation is not expressed until a second mutation, within a somatic cell, causes loss of the normal dominant allele. The mutations causing the inherited and sporadic tumours are similar but the cell types in which they occur are different. In the inherited tumours, the first mutation occurs in the germ cell, whereas in the sporadic tumours both mutations occur in the somatic cell. Thus, the risk of tumour development in an individual who has not inherited the first germline mutation is much smaller, as both mutational events must coincide in the same somatic cell. In addition, the apparent paradox that the

<table>
<thead>
<tr>
<th>Tumours</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoids (all, i.e. foregut, midgut and hindgut NETs)</td>
<td>&lt; 50</td>
</tr>
<tr>
<td>Pancreatic islet cell tumours</td>
<td></td>
</tr>
<tr>
<td>Gastrinomas</td>
<td>25</td>
</tr>
<tr>
<td>Insulinomas</td>
<td>15</td>
</tr>
<tr>
<td>VIPomas</td>
<td>6</td>
</tr>
<tr>
<td>Glucagonomas</td>
<td>3</td>
</tr>
<tr>
<td>Others</td>
<td>&lt; 1</td>
</tr>
</tbody>
</table>

The development of tumours may be associated with mutations or inappropriate expression of specific normal cellular genes, which are referred to as oncogenes (Thakker & Ponder 1988, Thakker 1993, 1994, Brown & Solomon 1997). Two types of oncogenes, referred to as dominant and recessive oncogenes, have been described. An activation of dominant oncogenes leads to transformation of the cells containing them, and examples of this are the chromosomal translocations associated with the occurrence of Burkitt’s lymphoma and the activating mutations of the RET proto-oncogene in MEN type 2. In these conditions, the mutations, which lead to activation of the oncogene, are dominant at the cellular level, and therefore only one copy of the mutated gene is required for the phenotypic effect. However, in some inherited neoplasms, which may also arise sporadically, such as retinoblastoma (RB) and MEN1, tumour development is associated with two recessive mutations, which inactivate oncogenes, and these are referred to as recessive oncogenes. In the inherited tumours, the first of the two recessive mutations is inherited via the germ cell line and is present in all the cells. This recessive mutation is not expressed until a second mutation, within a somatic cell, causes loss of the normal dominant allele. The mutations causing the inherited and sporadic tumours are similar but the cell types in which they occur are different. In the inherited tumours, the first mutation occurs in the germ cell, whereas in the sporadic tumours both mutations occur in the somatic cell. Thus, the risk of tumour development in an individual who has not inherited the first germline mutation is much smaller, as both mutational events must coincide in the same somatic cell. In addition, the apparent paradox that the
Table 2: Methylation patterns in foregut, midgut and hindgut NETs

<table>
<thead>
<tr>
<th>Gene</th>
<th>Methylation status</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin-dependent kinase inhibitor-2A (p16)</td>
<td>Colon &gt; stomach &gt; ileum &gt; PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Adenomatous polyposis of the colon (APC)</td>
<td>NSCLC &gt; SCLC &gt; AC and TC</td>
<td>Toyooka et al. (2001)</td>
</tr>
<tr>
<td>H-cadherin (CDH13)</td>
<td>NSCLC &gt; SCLC &gt; AC and TC</td>
<td>Toyooka et al. (2001)</td>
</tr>
<tr>
<td>O6-methylguanine-DNA-methyl transferase (MGMT)</td>
<td>Duodenum = rectum &gt; colon &gt; PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Retinoic acid receptor-β2 (RARβ)</td>
<td>Stomach = rectum &gt; ileum &gt; normal tissue &gt; PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>E-cadherin (CDH1)</td>
<td>SCLC &gt; AC and TC</td>
<td>Toyooka et al. (2001)</td>
</tr>
<tr>
<td>RAS-associated domain family 1A (RASSFIA)</td>
<td>SCLC &gt; AC and TC &gt; NSCLC</td>
<td>Toyooka et al. (2001)</td>
</tr>
<tr>
<td>p14 (cyclin-dependent kinase inhibitor-2D)</td>
<td>Stomach = rectum &gt; ileum &gt; PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Cyclo-oxygenase 2 (COX2)</td>
<td>Stomach = rectum &gt; colon &gt; ileum &gt; normal tissue = PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Oestrogen receptor (ER)</td>
<td>Stomach &gt; ileum &gt; PETs &gt; duodenum = colon &gt; normal tissue</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Thrombospondin 1 (THBS1)</td>
<td>Rectum &gt; duodenum = stomach &gt; colon &gt; ileum &gt; PETs</td>
<td>Chan et al. (2003)</td>
</tr>
<tr>
<td>Caspase 8 (CASP8)</td>
<td>SCLC &gt; AC and TC &gt; NSCLC</td>
<td>Shivapurkar et al. (2002)</td>
</tr>
</tbody>
</table>

*NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; AC, atypical lung carcinoid; TC, typical lung carcinoid.

Table 3: Dominant and recessive oncogenes altered in NETs

<table>
<thead>
<tr>
<th>Chromosomal location</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dominant oncogenes</td>
<td></td>
</tr>
<tr>
<td>K-ras</td>
<td>12p12.1</td>
</tr>
<tr>
<td>N-ras</td>
<td>1p13.2</td>
</tr>
<tr>
<td>Recessive oncogenes</td>
<td></td>
</tr>
<tr>
<td>Fragile histidine triad (FHIT)</td>
<td>3p14.2</td>
</tr>
<tr>
<td>APC</td>
<td>9p21</td>
</tr>
<tr>
<td>Mutated in colorectal cancer (MCC)</td>
<td>5p21</td>
</tr>
<tr>
<td>MEN1</td>
<td>11q13</td>
</tr>
<tr>
<td>Succinate-ubiquinone oxidoreductase subunit D (SDHD)*</td>
<td>11q23</td>
</tr>
<tr>
<td>Transforming protein 53 (p53)</td>
<td>17p13.1</td>
</tr>
</tbody>
</table>

*SDHD is unlikely to be involved as the reported alterations are polymorphisms.

The **MEN1** gene and NETs

NETs are commonly seen in patients with MEN1, which is an autosomal dominant disorder that is characterised by the combined occurrence of tumours of the parathyroid, pancreatic islet cells (e.g. gastrinomas, insulinomas, vasoactive intestinal polypeptidomas (VIPomas), glucagonomas, pancreatic polypeptidomas (PPomas) and non-functioning tumours), and anterior pituitary (e.g. prolactinomas, somatotrophinomas, corticotrophinomas and non-functioning tumours) (Thakker 2000, Pannett & Thakker 2001). Other associated tumours may also arise in MEN1 patients and these include adrenal cortical tumours, bronchial NETs, thymic NETs, lipomas, collagenomas and angiofibromas (Trump et al. 1996). The **MEN1** gene on chromosome 11q13 represents a putative tumour suppressor gene, consistent with the Knudson model for tumour development (Knudson 1974, Pannett & Thakker 2001). The **MEN1** gene consists of 10 exons which span > 9 kb of genomic DNA (Chandrasekharappa et al. 1997, The European Consortium on MEN1 1997) (Fig. 3). The 1.83

---

Endocrine-Related Cancer (2003) 10 437–450
kb mRNA encodes a novel 610 amino acid protein referred to as MENIN (Chandrasekharappa et al. 1997). Over 600 germline mutations of the MEN1 gene have been identified and these are scattered throughout the coding region and are of diverse types (Pannett & Thakker 1999, Turner et al. 2002). Thus, approximately 21% are nonsense, 44% are frameshift deletions or insertions, 9% are in-frame deletions or insertions, 7% are splice site mutations and 19% are missense mutations (Turner et al. 2002). Such germline MEN1 mutations are frequently associated with NETs and this is illustrated by family 7/03 (Fig. 4), in which affected members have a missense MEN1 mutation and develop different NETs that include gastrinomas, insulinomas and lung NETs (Trump et al. 1996, The European Consortium on MEN1 1997). The majority of MEN1 tumours have LOH of chromosome 11q13 and a few have been shown to harbour somatic mutations consistent with the Knudson two-hit hypothesis (Pannett & Thakker 2001). In addition, LOH at the MEN1 locus on chromosome 11q13 and somatic MEN1 mutations have also been observed in sporadic NETs of foregut origin, thereby indicating a role for the MEN1 gene in the aetiology of such tumours (Toliat et al. 1997, Zhuang et al. 1997b, Hesselman et al. 1998, Shan et al. 1998, Wang et al. 1998, Fujii et al. 1999, Gortz et al. 1999, Mailman et al. 1999, Bergman et al. 2000, Goebel et al. 2000, Pannett & Thakker 2001). Thus, LOH at chromosome 11q13 has been shown in approximately 60% of sporadic foregut NETs and pancreatic islet-cell tumours, which include gastrinomas, insulinomas, VIPomas and glucagonomas (Jakobovitz et al. 1996, Debelenko et al. 1997a, Dong et al. 1997, Emmert-Buck et al. 1997, Toliat et al. 1997, D’Adda et al. 1999b). In addition, somatic MEN1 mutations have, to date, been reported in 11 sporadic foregut NETs, excluding pancreatic NETs (Table 4 and Fig. 3) (Debelenko et al. 1997a, 2000, Baudin et al. 1999, Fujii et al. 1999, Gortz et al. 1999). The mutations consist of three nonsense mutations, six frameshift deletions and insertions, one missense mutation and one donor splice site mutation. The nonsense, frameshift and donor splice site mutations are predicted to lead to truncated MENIN proteins, and these and the form resulting from the missense mutation are likely to disrupt the functions of MENIN (see below) by altering its binding to interacting proteins (Fig. 5).

**Function of MENIN**

MENIN is predominantly a nuclear protein in non-dividing cells, but in dividing cells it is also found in the cytoplasm (Guru et al. 1998). The function of MENIN still remains to be elucidated, but it has been shown to interact with a number of proteins that are involved in transcriptional regulation and the control of genome stability. Thus, in transcriptional regulation, MENIN has been shown to interact with: (i) the activating protein-1 transcription factors JunD (Agarwal et al. 1999) and c-Jun (Yumita et al. 2003) to suppress Jun-mediated transcriptional activation; (ii) members of...
the NF-κB family (e.g. p50, p52 and p65) of transcription regulators to repress NF-κB-mediated transcriptional activation (Heppner et al. 2001); (iii) members of the Smad family (Smad 3, Smad1/5 complex) to modulate the transforming growth factor-β (TGFβ) pathway (Kaji et al. 2001) and the bone morphogenetic protein-2-signalling pathways, respectively (Sowa et al. 2003); and (iv) the mouse placenta and embryonic expression (Pem) gene, which encodes a homeobox containing protein that plays a role in transcription (Lemmens et al. 2001). A role for MENIN in controlling genome stability has been reported because it interacts with: (i) a subunit of RPA2, which is a heterotrimeric protein required for DNA replication, recombination and repair (Sukhodolets et al. 2003); (ii) the tumour metastases suppressor NM23H1/nucleoside diphosphate kinase (Ohkura et al. 2001, Yaguchi et al. 2002), which induces GTPase activity; and (iii) the glial fibrillary acidic protein and vimentin (Lopez-Egido et al. 2002), which are involved in the intermediate filament network. The 11 somatic MEN1 mutations reported in the sporadic NETs (Table 4) are predicted to disrupt these protein interactions (Fig. 5) and hence the function of MENIN in regulating cell proliferation.

Other genes involved in NETs

Foregut NETs

The NETs that have been studied for genetic abnormalities are principally from the lung (bronchial), thymus, stomach and pancreas and each has the involvement of different genes.

Lung NETs

Lung NETs represent a broad spectrum of morphological types, ranging, in order of aggressiveness and malignant potential, from typical carcinoids (TC), atypical carcinoids
Figure 3: Schematic representation of the genomic organisation of the MEN1 gene illustrating 11 somatic mutations found in non-familial, i.e. sporadic isolated (i.e. non-MEN1 patients) bronchial, thymic, gastric and duodenal NETs (see Table 4). The human MEN1 gene consists of 10 exons that span > 9 kb of genomic DNA and encodes a 610 amino acid protein (Chandrasekharappa et al. 1997, The European Consortium on MEN1 1997). The 1.83 kb coding region is organised into 9 exons (exons 2–10) and 8 introns (indicated by a line but not to scale). The sizes of the exons (solid boxes) range from 42 to 1312 bp and those of the introns range from 41 to 1564 bp. The start (ATG) and stop (TGA) sites in exons 2 and 10 respectively, are indicated. Exon 1, the 5′ part of exon 2 and 3′ part of exon 10 are untranslated (indicated by hatched boxes). The locations of the two nuclear localisation sites, which are at codons 479 to 497, and 588 to 608 at the C-terminus, are represented by horizontally hatched boxes in exon 10. The sites of the 11 somatic mutations (three nonsense mutations, six frameshift mutations, one missense mutation and one donor splice site mutation) found in sporadic NETs are represented below the gene, and details of each of these are provided in Table 4.

LOH at chromosome 3p is the most frequent change in lung NETs and has been observed in 40% of TC, 25% of AC, 83% of LCNEC and 85% of SCLC (Onuki et al. 1999). The other abnormalities that were found in approximately 10% of lung NETs included gains of chromosomes 5, 7, 8, 9q, 14q, 15q, 16q, 17 and 20q, and losses of chromosome 1p, 6q and 22q (Zhao et al. 2000). Further studies of such tumours are required to clarify the chromosomal abnormalities associated with these foregut NETs.

LOH at chromosome 3p is the most frequent change in lung NETs and has been observed in 40% of TC, 73% of AC, 83% of LCNEC and 85% of SCLC (Onuki et al. 1999). The FHIT locus at chromosome 3p14.2 has been particularly studied and LOH was observed in 23% of TC, 35%-50% of AC, 80% of LCNEC and 67% of SCLC, but no somatic mutations have been reported (Kovatich et al. 1999a, Onuki et al. 1999). The frequency of LOH on chromosome 5q21, which is the location of the APC/MCC genes, increases with the severity of the tumour. Thus, LOH at chromosome 5q21 was observed in 0% of TC, 25% of AC, 46% of LCNEC and 86% of SCLC and was correlated with a poor survival in patients with lung NETs (Onuki et al. 1999). Furthermore, a meta-analysis using data from the literature revealed that LOH at chromosome 5q in lung neuroendocrine carcinomas (LCNEC and SCLC) was higher, at 75%, than in lung carcinoid tumours (TC and AC) in which the frequency was 1.4% (Ullmann et al. 2002). LOH at chromosome 9p21, which is the location of the p16 locus, is also higher in carcinomas (53%) than in the carcinoid tumours (23%) (Onuki et al. 1999). LOH and point mutations of the p53 locus on chromosome 17p13 were detected in 10% of TC (Lohmann et al. 1993a, Ramnani et al. 1999), 45% of AC (Hiyama et al. 1993, Couce et al. 1999), 72% of LCNEC (Lohmann et al. 1993a, Couce et al. 1999) and 90% of SCLC (Sameshima et al. 1992). Furthermore, these p53 alterations in lung NETs were found to correlate with poor survival rates amongst patients (Onuki et al. 1999). LOH at the RB locus on chromosome 13q14.1-q14.2 also increased with the aggressiveness of the tumour such that there was a demarcation between the lung carcinoids (AC and TC) and the carcinomas (LCNEC and SCLC), thereby suggesting that different mechanisms may be involved in tumorigenesis in these two types of lung NETs (Onuki et al. 1999). Furthermore, two mutations of K-ras, which is a dominant oncogene that is aberrant in most human tumours including lung cancer (Nakano et al. 1984), have been found in atypical lung NETs (Couce et al. 1999). Overall,
Figure 4 Detection of MEN1 mutation (Trp183Stop) in exon 3 in family 7/03 by restriction enzyme analysis. DNA sequence analysis of individual II-5 revealed a G → A transition at the third nucleotide of codon 183. The transition results in the loss of a BstNI restriction enzyme site (CC/TGG) from the WT sequence (A), and this has facilitated the detection of the mutation in the other affected members (II.2, II.4, II.5, III.1, III.3, III.4, III.6 and III.9) of this family (B). The mutant (m) PCR product is 97 bp (C), whereas the WT products are 111, 118, 51 and 45 bp. The 51 and 45 bp products are not shown. The affected individuals are heterozygous (WT/m), and the unaffected family members (I.1, II.6, II.7, III.2, III.5, III.7 and III.8) and control unrelated normals (N1–N3) are homozygous for the WT allele (B). Individuals are represented as males (squares), females (circles), unaffected (open symbols), affected with parathyroid tumours (solid upper right quadrant), affected with corticotrophinoma (solid lower right quadrant), affected with pancreatic tumour (solid lower left quadrant; G, gastrinoma, I, insulinoma and U, unknown) and affected with lung NET (solid upper left quadrant). The positions of the size markers (S) at 100 bp and 200 bp are shown.

Cosegregation of this mutation with MEN1 in family 7/03 and its absence from 110 alleles of 55 unrelated normal individuals (N1–N3 shown) was demonstrated, thereby indicating that it is not a common polymorphism. The clinical findings in this family, 7/03, with the Trp183Stop mutation have been updated from those previously reported as family 7/87 (Trump et al. 1996, The European Consortium on MEN1 1997).

These studies of lung NETs reveal four important findings: (i) LOH at chromosome 3p is the most frequent change in these tumours; (ii) LOH of the MEN1 locus is also common; (iii) LOH and mutations of p53 cumulatively increase with severity of the tumour type; and (iv) LOH at 5q21, the location of the APC and MCC genes is correlated with a poor survival.

In addition to these studies of LOH, CGH and mutational analysis, lung NETs have also been investigated for silencing of genes by methylation. Genes that are frequently methylated in gastrointestinal malignancies were investigated in lung TCs, ACs, SCLCs and NSCLC, and the frequencies of methylation of the RARβ, CDH1, RASSF1A and CASP8 genes were found to be higher in SCLC (45%, 55%, 80% and 35% respectively) than in TCs and ACs (20%, 25%, 55% and 18% respectively), although ACs seemed to have a higher frequency (71%) of RASSF1A methylation when compared with TCs (45%). However, methylation of the RASSF1A, p16, APC and CDH13 genes was significantly higher in NSCLCs when compared with the lung NETs (TC, AC and SCLC) (Toyooka et al. 2001, Shivapurkar et al. 2002). These methylation differences between lung TCs, ACs, SCLCs and NSCLC reinforce the view that these tumours are fundamentally different and that the tumorigenic
Table 4 Somatic MEN1 mutations in sporadic foregut NETs, excluding those of the pancreas

<table>
<thead>
<tr>
<th>Mutation type; number</th>
<th>Exon</th>
<th>Codon</th>
<th>Base change</th>
<th>Predicted effect</th>
<th>Tissue</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsense</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Exon 2</td>
<td>108</td>
<td>CGA → TGA</td>
<td>ns, Arg108 Stop</td>
<td>Bronchial</td>
<td>Baudin et al. (1999)</td>
</tr>
<tr>
<td>2</td>
<td>Exon 3</td>
<td>209</td>
<td>CAG → TAG</td>
<td>ns, Gln209 Stop</td>
<td>Duodenal</td>
<td>Gortz et al. (1999)</td>
</tr>
<tr>
<td>3</td>
<td>Exon 8</td>
<td>393</td>
<td>CAA → TAA</td>
<td>ns, Gln393 Stop</td>
<td>Thymic</td>
<td>Fujii et al. (1999)</td>
</tr>
<tr>
<td>Deletion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Exon 2</td>
<td>8–12 nt</td>
<td>nt134del13bp</td>
<td>fs, ins 108 aa Stop</td>
<td>Bronchial</td>
<td>Debelenko et al. (1997a)</td>
</tr>
<tr>
<td>5</td>
<td>Exon 2</td>
<td>83–84 nt</td>
<td>nt357del4p</td>
<td>fs, ins 34 aa Stop</td>
<td>Stomach</td>
<td>Fujii et al. (1999)</td>
</tr>
<tr>
<td>6</td>
<td>Exon 8</td>
<td>372</td>
<td>nt1226delC</td>
<td>fs, ins 3 aa Stop</td>
<td>LCNEC 4</td>
<td>Debelenko et al. (2000)</td>
</tr>
<tr>
<td>7</td>
<td>Exon 10</td>
<td>451</td>
<td>nt1461delG</td>
<td>fs, ins 7 aa Stop</td>
<td>Bronchial</td>
<td>Debelenko et al. (1997a)</td>
</tr>
<tr>
<td>Insertion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Exon 2</td>
<td>108</td>
<td>nt134ins29bp</td>
<td>fs, ins 10 aa Stop</td>
<td>Bronchial</td>
<td>Gortz et al. (1999)</td>
</tr>
<tr>
<td>9</td>
<td>Exon 10</td>
<td>514</td>
<td>nt1650insC</td>
<td>fs, ins 44 aa Stop</td>
<td>Bronchial</td>
<td>Debelenko et al. (1997a)</td>
</tr>
<tr>
<td>Missense</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Exon 3</td>
<td>172</td>
<td>GAT → TAT</td>
<td>ms, Asp172Val</td>
<td>Bronchial</td>
<td>Gortz et al. (1999)</td>
</tr>
<tr>
<td>Donor splice site mutation</td>
<td>Exon 3</td>
<td>172</td>
<td>nt764+3 (ag)</td>
<td>ds, fs, ins 18 aa Stop</td>
<td>Bronchial</td>
<td>Debelenko et al. (1997a)</td>
</tr>
</tbody>
</table>

*Somatic* MEN1 mutations have been found in sporadic pancreatic NETs, including gastrinomas (Zhuang et al. 1997a, Wang et al. 1998, Mailman et al. 1999, Goebel et al. 2000), insulinomas (Zhuang et al. 1997a, Shan et al. 1998, Pannett & Thakker 2001), VIPomas (Shan et al. 1998, Wang et al. 1998, Gortz et al. 1999) and glucagonomas (Hessman et al. 1998, Bergman et al. 2000). Midgut and hindgut NETs generally do not have MEN1 mutations, though a missense mutation, Val53Ile, has been identified in one ileal NET (Gortz et al. 1999).

process in each type evolves along different pathways with tumours of the same histological type having similar methylation patterns. Furthermore, methylation of the death-associated protein kinase and APC genes in lung cancers has also been shown to correlate with poor survival (Tang et al. 2000, Virmani et al. 2001). These studies are important as they may have a potential impact on the clinical management of patients, as treatment with demethylating agents, which results in a temporary restoration of gene expression, may represent a potential method of tumour therapy or chemoprevention (Momparler et al. 2000, Schwartsmann et al. 2000) in patients who have tumours with such methylated genes.

**Thymic NETs**

The genetic abnormalities in thymic NETs have not been as well characterised as the other foregut NETs. Twenty five per cent of reported thymic NETs are from MEN1 patients (Teh 1998), and LOH of the MEN1 locus on chromosome 11q13 has not been reported in thymic NETs, though a somatic MEN1 mutation has been reported in one thymic NET (Teh 1998, Fujii et al. 1999, Hessman et al. 2001). LOH of chromosome 1p has been reported in two thymic NETs (Teh et al. 1998), and our CGH results (Table 5) reveal the occurrence of deletions of chromosomes 3, 9p21-pter, and Y and a gain of chromosome 19p in a thymic NET from a male patient.

**Gastric NETs**

Gastric NETs are derived from the enterochromaffin-like (ECL) cell. Four main types referred to as ECL types I–III (ECL-I to -III) and neuroendocrine carcinoma are recognised depending upon their clinical and pathological characteristics (Rindi et al. 1993, Bordi 1995). ECL-I tumours, which are associated with atrophic gastritis and hypergastrinaemia, account for 70–80% of all ECLomas and consist of small, multiple tumours that are limited to the mucosa or submucosa, and rarely metastasise to regional lymph nodes. More than 85% of ECL-I tumours are monoclonal (D’Adda et al. 1999a). ECL-II tumours, which are associated with MEN1 and the Zollinger–Ellison syndrome, account for 6% of ECLomas and consist of multiple tumours that infiltrate to
Figure 5 Schematic representation of the amino acid sequence of MENIN together with the regions that interact with other proteins. (A) MENIN has two nuclear localisation signals (horizontally hatched boxes) at codons 479–497 and 588–608 (Guru et al. 1998), and 5 putative GTPase sites (G1–G5) (open boxes), whose consensus sequences are shown above, with the conserved amino acid residues shown in bold (Yaguchi et al. 2002). (B) MENIN regions that likely interact with JunD (codons: 1–40, 139–242, 323–428) (Agarwal et al. 1999); nuclear factor-κB (NF-κB) (codons: 305–381) (Heppner et al. 2001); small-mothers against decapentaplegic homology 3, Smad3 (codons: 40–278, 477–610) (Kaji et al. 2001); placenta and embryonic expression, Pem (codons: 278–476) (Lemmens et al. 2001); non-metastatic 23β human genes, NM23H1 (codons: 1–486) (Ohkura et al. 2001); and a subunit of replication protein A (RPA2) (codons 1–40, 286–448) (Sukhodolets et al. 2003) are indicated by the boxes with grey shading. (C) Truncated or other abnormal forms of MENIN that are predicted to result from the 11 somatic MEN1 mutations reported in sporadic foregut NETs, excluding pancreatic neuroendocrine tumours, are represented by bars (normal sequence, solid bars and missense sequences, open bars).

Table 5 CGH analysis of eight NETs (seven lung TCs and a thymic NET)

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Sex</th>
<th>NET</th>
<th>Chromosomal losses</th>
<th>Chromosomal gains</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>Lung TC</td>
<td>11q12-pter, 11p13-pter</td>
<td>19</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>Lung TC</td>
<td>22q13-pter</td>
<td>13, 19</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>Lung TC</td>
<td>14, 17, 19, 20q, 22q</td>
<td>5, 19</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>Lung TC</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>Lung TC</td>
<td>1p21-qter, 2q34-qter, 3</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>Lung TC</td>
<td>8p23-qter, 17q</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>Lung TC</td>
<td>3, 9p21-pter, Y</td>
<td>19p, X</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>Thymus</td>
<td>19p</td>
<td></td>
</tr>
</tbody>
</table>

Sex: M, Male; F, Female.

p, Short arm of a chromosome; q, long arm of a chromosome; ter, telomeric.

TC, typical carcinoid.
the submucosa. The prognosis for ECL-II tumours is generally good, even if they occasionally become aggressive (Rindi et al. 1993, Bordi 1995). ECL-III tumours, which are associated with hypergastrinaemia, account for 14–25% of ECLomas and usually consist of a single tumour that is often infiltrating the muscularis propria and serosa. ECL-III tumours, which may have LOH of the X chromosome (D’Adda et al. 1999a), frequently metastasise, and hepatic metastases occur in 50% of patients who have a poor prognosis. Neuroendocrine carcinomas, which are uncommon, are usually single, large, poorly differentiated and highly malignant, and LOH on chromosomes 8p, 11p, 12p, 13q, 15q and 17p has been reported in 82%, 50%, 50%, 50%, 58% and 57% of 15 such tumours respectively (Han et al. 2000). LOH of the MEN1 locus on chromosome 11q13 has been found in 48% of 25 ECL-I tumours (D’Adda et al. 1999b), 75% of 20 ECL-II tumours (Debelenko et al. 1997b) and both of two neuroendocrine carcinomas (D’Adda et al. 1999b). Somatic MEN1 mutations have not been detected in type I and III ECLomas, but a 4 bp deletion at codon 83 of SDHD gene (Table 4 and Figs 3 and 5) has been reported in one gastric neuroendocrine carcinoma (Fuji et al. 1999).

**Pancreatic NETs**

All pancreatic NETs from MEN1 patients have shown a loss (LOH) of chromosome 11. However, 30% of these tumours may also show LOH at chromosomes 3, 6, 8, 10, 18 and 21 (Hessman et al. 2001). In addition, LOH at chromosomes 3 and 6 is also observed in > 50% and > 60% of sporadic (i.e. non MEN1) pancreatic NETs respectively. The chromosome 3 losses particularly occur as late events, thereby suggesting that putative tumour suppressor genes on this chromosome may be involved in a more aggressive tumour phenotype (Barghorn et al. 2001, Guo et al. 2002). Furthermore, a point mutation of the N-Ras gene has been identified in a PET (Arany et al. 1994).

**Midgut NETs (carcinoids)**

In contrast to foregut NETs, which have frequent deletions and mutations of the MEN1 gene, midgut NETs (i.e. carcinoids) rarely show involvement of the MEN1 gene. However, CGH studies have shown losses of chromosome 11q in 22% of ileal and duodenal carcinoids, and this has involved the distal part of chromosome 11q, where the tumour suppressor gene SDHD is located (Kyotela et al. 2002). Germline mutations of SDHD have been reported in families with hereditary head and neck paragangliomas linked to 11q23, and in families with adrenal and extra-adrenal phaeochromocytomas (Baysal et al. 2000, Gimm et al. 2000, Astuti et al. 2001ab, Badenhop et al. 2001, Milunsky et al. 2001, Taschner et al. 2001). Two possible germine missense mutations (His50Arg and Gly12Ser) of the SDHD gene were reported in two sporadic midgut carcinoid tumours, which also had LOH at the SDHD locus on chromosome 11q23 (Kyotela et al. 2002). There is debate about whether these changes are mutations or polymorphisms, particularly as Gly12Ser has been reported in a phenotypically normal patient (Gimm et al. 2000) and it has also been reported that His50Arg may represent a rare polymorphism. Furthermore, SDHD mutations have not been detected in 45 NETs of the lung, gastrointestinal, pancreatic and parathyroid (Perren et al. 2001), and thus it would seem unlikely that the SDHD gene is involved in midgut NETs which are likely to be due to other genes. Indeed CGH studies of midgut carcinoids have shown losses of chromosomes 9p, 18p and 18q in 21%, 38% and 33% respectively (Zhao et al. 2000, Tonnessies et al. 2001), gains of chromosomes 17q and 19p in 57% (Tonnessies et al. 2001) and LOH of chromosome 18 has been reported in 88% of midgut NETs (Lollgen et al. 2001). In addition, 22% of midgut tumours have losses of 16q21 and metastases show an accumulation of genetic abnormalities, which particularly involve a loss of chromosome 16q and a gain of chromosome 4p. Furthermore, a K-ras mutation, Gly12Asp, has been identified in an extra-hepatic bile duct NET (Maitra et al. 2000). These findings indicate that midgut and foregut NETs are likely to develop via different molecular pathways, although the genes involved at chromosomes 4p, 9p, 16q, 18p and 18q, in causing midgut carcinoids, remain to be identified. Appendiceal goblet-cell carcinoids may have yet another molecular pathway of development as up-regulation of cyclin D1 and p21 together with down-regulation of p16 have been reported (Kanthan et al. 2001, Oberg 2002).

**Hindgut NETs**

The genetic abnormalities in hindgut NETs have not been as well characterised as those in foregut and midgut NETs, and LOH of chromosome 18 has been identified in only one ascending colon NET (Lollgen et al. 2001). Rectal NETs that are > 5 mm in size have been reported to express TGFr more frequently, and the epidermal growth factor (EGF) receptor was expressed in all lesions (Shimizu et al. 2000). It has therefore been proposed that TGFr and the EGF receptor may participate in an autocrine mechanism that regulates the growth of hindgut NETs, and hence these hindgut tumours are likely to develop via different molecular pathways from those of the foregut and midgut NETs (Shimizu et al. 2000).

**Conclusion**

NETs may occur as part of complex familial endocrine cancer syndromes such as MEN1 and NF1, although the majority occur as non-familial (i.e. sporadic) isolated tumours. Different genes are involved in the aetiology of each type of NET and different genetic abnormalities that...
include point mutations, gene deletions, DNA methylation, chromosomal losses and chromosomal gains may be involved. Furthermore, the foraged, midgut and hindgut NETs develop via different molecular pathways. For example, foraged NETs have frequent deletions and mutations of the \textit{MEN1} gene, whereas midgut NETs have losses of chromosomes 18, 11q and 16q, and hindgut NETs, express TGF\(_\beta\) and the EGF receptor. In addition, in lung NETs, a loss of chromosome 3p is the most frequent change, and p53 mutations and chromosomal loss of 5q21 are associated with more aggressive tumours and poor survival. Moreover, methylation frequencies of RAR\(_\beta\), CDHI and RASSF1A genes increase with the severity of lung NETs. Thus the development and progression of NETs is associated with specific genetic abnormalities that indicate the likely involvement of different molecular pathways.

**Acknowledgements**

This work was supported by the Medical Research Council, UK (P D L and R V T), the Rhodes Trust (P D L), the Wingate Trust, UK (P D L), and the Evelyn Coombes Memorial Fund (P D L and R V T). Informed verbal consent was obtained from all of the individuals, using the guidelines approved by the local ethics committees at the Hammersmith Hospital, Royal Postgraduate Medical School (London, UK).

**References**


Debelemko LV, Emmert-Buck MR, Zhuang Z, Epstein EY, Moskaluk CA, Jensen RT, Liotta LA & Lubensky IA 1997b The multiple endocrine neoplasia type 1 gene locus is involved in the


Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, Miyazono K, Sugimoto T & Chihara K 2003 Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. Journal of Biological Chemistry 278 21058–21069.